EGEN receives FDA orphan drug grant for ovarian cancer drug
The company has successfully completed two Phase I trials of EGEN-001, in which the treatment resulted in good safety, biological activity and encouraging efficacy. EGEN-001 received Orphan Drug
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.